ReviewCurrent urology reports2025
Off-Label but On-Target: Sacral Neuromodulation for Neurogenic Bladder Dysfunction.
Review in Current urology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- SPI1 exacerbates neurogenic bladder dysfunction by enhancing NRSF-mediated suppression of HCN1 and inducing endoplasmic reticulum stress.In vitro cellular & developmental biology. Animal · 2026Article
- Prior Authorization for Sacral Nerve Stimulation in the Era of WISeR: Evaluation of U.S. Payer Coverage Policies.Neurourology and urodynamics · 2026Article
- Should We Consider Sacral Nerve Stimulation as a Treatment for Neurogenic Lower Urinary Tract Dysfunction? ICI-RS 2025.Neurourology and urodynamics · 2026Review
- Sacral Neuromodulation Outcomes for Managing Urinary Incontinence in Patients With Overactive and Neurogenic Bladder.Cureus · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewNeurogenic bladder dysfunction (NBD) is a frequent complication of neurological diseases including Parkinson's disease, multiple sclerosis, spinal cord injury, and spina bifida. Managing NBD remains challenging, especially for patients who fail to respond to standard therapies. Sacral neuromodulation (SNM), though FDA-approved for non-neurogenic conditions, is increasingly explored off-label in neurogenic populations. RECENT
findingsRecent studies demonstrate that SNM can improve lower urinary tract symptoms, bladder storage, and emptying in select NBD patients. Small case series and retrospective reviews suggest reduced catheterization and medication use. Technological advances, such as closed-loop systems and MRI-compatible devices, are broadening SNM's clinical potential. SNM is emerging as a valuable, minimally invasive treatment for neurogenic bladder dysfunction. Careful patient selection and understanding of underlying pathophysiology are essential for success. As evidence grows and device innovations continue, SNM could reshape management strategies for patients with neurogenic bladder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.